IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#2565
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$52M
Someit Sidhu
Zura Bio Limited is a clinical-stage biotechnology company advancing immunology assets into Phase 2 development programs, including ZB-168 and Torudokimab. ZB-168 is an anti IL7R α inhibitor that has the potential to impact diseases driven by IL7 and TSLP biological pathways. Zura aims to develop a portfolio of therapeutic indications for ZB-168 which build on existing Phase 1b data in Type 1 Diabetes demonstrating a favorable safety profile and strong biological rationale. Torudokimab is a fully human, high affinity monoclonal antibody that neutralizes IL33 and is currently at the Phase 2 clinical development stage.
Headcount
3
HQ Base
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ZURA Zura Bio Ltd | 47 | 28 | 23 | 92 | - | - | -65.7% | -50.1% | - | - | - | - | 0.0% | 23.0x | $52M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
Zura Bio Ltd (ZURA) receives a "Reduce" rating with a composite score of 46.5/100. It ranks #2565 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Pending Verification
Outperforming peers — winners tend to keep winning over 3-12 months
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for ZURA.
View All Ratings| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 28 | 14 | +14ALPHA |
| MOMENTUM | 92 | 96 | -4NEUTRAL |
| VALUATION | 23 | 12 | +11ALPHA |
| INVESTMENT | 25 | 13 | +12ALPHA |
| STABILITY | 33 | 20 | +13ALPHA |
| SHORT INT | 35 | 27 | +8ALPHA |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy -65.7% (sector -1.9%)
GM N/A vs sector 44%, OM N/A vs sector 3%
Capital turnover N/A
Rev growth N/A, 4yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate Zura Bio Ltd (ZURA) as a Reduce with a composite score of 46.5/100 at a current price of $6.35. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential.
Zura Bio Ltd holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 46.5/100 places it at rank #2565 in our full universe.
No Moat
High
Poor
Fair Value
Positive momentum indicates institutional accumulation.
Stable competitive position in a defensive sector.
Below-average quality raises earnings sustainability concerns.
Vulnerability to macroeconomic shocks and interest rate volatility.
Zura Bio Ltd represents a reduce based on multi-factor quantitative performance.
Zura Bio Ltd receives a Reduce rating from our analysis, with a composite score of 46.5/100 and 2 out of 5 stars, ranking #2565 out of 7,333 stocks. ZURA's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
ZURA's quality score of 28/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -65.7% (sector avg: -1.9%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
ZURA registers a value score of just 23/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 3.67x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
Zura Bio Ltd's investment score of 25/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of -50.1% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
Zura Bio Ltd (ZURA) is exhibiting exceptional momentum with a score of 92/100, placing it among the strongest trending stocks in the market. Revenue growth data is not currently available, while a beta of 1.48 reflects its sensitivity to broader market moves. Stocks with momentum scores this high have historically outperformed over the following 3–12 months, suggesting ZURA may continue to benefit from strong institutional interest and positive price trends.
ZURA's stability score of 33/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 1.48 and a debt-to-equity ratio of 23.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
Zura Bio Ltd's short interest score of 35/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include above-average market sensitivity (beta: 1.48), elevated leverage (D/E: 23.00x), micro-cap liquidity risk. At $52M (micro-cap), ZURA carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
Zura Bio Ltd is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #2565 of 7,333 overall (65th percentile). Key comparisons include ROE of -65.7% trailing the -1.9% sector median. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While ZURA currently exhibits a REDUCE profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Value (23) would have the largest impact on the composite score.
ROE 3360% ABOVE SECTOR MEDIAN (FAVORABLE)
Debt/Equity 10852% ABOVE SECTOR MEDIAN
Div. Yield NaN% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
Zura Bio Ltd (NASDAQ:ZURA) saw its stock rise 5.4% after appointing Sandeep Kulkarni, M.D., as its new CEO, effective January 21, 2026. Dr. Kulkarni previously co-founded Tourmaline Bio and brings extensive experience to Zura, a clinical-stage biotechnology company developing tibulizumab for autoimmune diseases. The company anticipates two significant clinical readouts within the next 18 months.
Zura Bio (NASDAQ:ZURA) stock increased by 5.4% after announcing the appointment of Sandeep Kulkarni, M.D., as its new CEO, effective January 21, 2026. Dr. Kulkarni, who previously co-founded Tourmaline Bio, has been a director at Zura since its Nasdaq listing in 2023. Zura Bio is currently developing tibulizumab, a bispecific antibody for autoimmune diseases, with two significant readouts expected within the next 18 months.
Zura Bio Limited announced the appointment of Sandeep Kulkarni, M.D. as its new Chief Executive Officer, effective January 21, 2026. Dr. Kulkarni previously co-founded and served as CEO of Tourmaline Bio, guiding its acquisition by Novartis, and has been a director at Zura Bio since March 2022. He will lead Zura Bio as it advances its lead bispecific antibody program, tibulizumab, through key clinical readouts.
Zura Bio (NASDAQ: ZURA) has announced a significant leadership transition. Robert Lisicki resigned as CEO, effective January 21, 2026, and will receive a severance package. Dr. Sandeep Kulkarni, a current director, has been appointed as the new CEO with a substantial compensation package, and Parvinder Thiara has been added to the board as a new director, also receiving compensation in cash and stock options.
Zura Bio Limited reported that Arnout Ploos van Amstel resigned from its Board of Directors and the Nominating and Governance Committee, effective December 11, 2025. The company stated that his resignation was not due to any disagreement with its operations, policies, or practices. This disclosure is a standard governance change for the emerging growth company, whose Class A ordinary shares trade on Nasdaq under the symbol ZURA.